These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia. Sokolenko AP; Rozanov ME; Mitiushkina NV; Sherina NY; Iyevleva AG; Chekmariova EV; Buslov KG; Shilov ES; Togo AV; Bit-Sava EM; Voskresenskiy DA; Chagunava OL; Devilee P; Cornelisse C; Semiglazov VF; Imyanitov EN Fam Cancer; 2007; 6(3):281-6. PubMed ID: 17333477 [TBL] [Abstract][Full Text] [Related]
4. BRCA1 gene-related hereditary susceptibility to breast and ovarian cancer in Latvia. Tihomirova L; Vaivade I; Fokina O; Peculis R; Mandrika I; Sinicka O; Stengrevics A; Krilova A; Keire G; Petrevics J; Eglitis J; Timofejevs M; Leja M Adv Med Sci; 2014 Mar; 59(1):114-9. PubMed ID: 24797986 [TBL] [Abstract][Full Text] [Related]
5. BRCA1 mutations and prostate cancer in Poland. Cybulski C; Górski B; Gronwald J; Huzarski T; Byrski T; Debniak T; Jakubowska A; Wokołorczyk D; Gliniewicz B; Sikorski A; Stawicka M; Godlewski D; Kwias Z; Antczak A; Krajka K; Lauer W; Sosnowski M; Sikorska-Radek P; Bar K; Klijer R; Romuald Z; Małkiewicz B; Borkowski A; Borkowski T; Szwiec M; Posmyk M; Narod SA; Lubiński J Eur J Cancer Prev; 2008 Feb; 17(1):62-6. PubMed ID: 18090912 [TBL] [Abstract][Full Text] [Related]
6. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer. Hamel N; Kotar K; Foulkes WD BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837 [TBL] [Abstract][Full Text] [Related]
7. Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia. Plakhins G; Irmejs A; Gardovskis A; Subatniece S; Rozite S; Bitina M; Keire G; Purkalne G; Teibe U; Trofimovics G; Miklasevics E; Gardovskis J BMC Med Genet; 2011 Oct; 12():147. PubMed ID: 22032251 [TBL] [Abstract][Full Text] [Related]
8. Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer. Hebbring SJ; Fredriksson H; White KA; Maier C; Ewing C; McDonnell SK; Jacobsen SJ; Cerhan J; Schaid DJ; Ikonen T; Autio V; Tammela TL; Herkommer K; Paiss T; Vogel W; Gielzak M; Sauvageot J; Schleutker J; Cooney KA; Isaacs W; Thibodeau SN Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):935-8. PubMed ID: 16702373 [TBL] [Abstract][Full Text] [Related]
9. High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia. Tikhomirova L; Sinicka O; Smite D; Eglitis J; Hodgson SV; Stengrevics A Fam Cancer; 2005; 4(2):77-84. PubMed ID: 15951956 [TBL] [Abstract][Full Text] [Related]
10. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland. Cybulski C; Lubiński J; Wokołorczyk D; Kuźniak W; Kashyap A; Sopik V; Huzarski T; Gronwald J; Byrski T; Szwiec M; Jakubowska A; Górski B; Dębniak T; Narod SA; Akbari MR Clin Genet; 2015 Oct; 88(4):366-70. PubMed ID: 25330149 [TBL] [Abstract][Full Text] [Related]
11. Clinical, molecular and geographical features of hereditary breast/ovarian cancer in latvia. Gardovskis A; Irmejs A; Miklasevics E; Borosenko V; Bitina M; Melbarde-Gorkusa I; Vanags A; Kurzawski G; Suchy J; Górski B; Gardovskis J Hered Cancer Clin Pract; 2005 Apr; 3(2):71-6. PubMed ID: 20223033 [TBL] [Abstract][Full Text] [Related]
12. Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia. Mutation in brief no. 258. Online. Csokay B; Tihomirova L; Stengrevics A; Sinicka O; Olah E Hum Mutat; 1999; 14(1):92. PubMed ID: 10447273 [TBL] [Abstract][Full Text] [Related]
13. BRCA1 mutations do not increase prostate cancer risk: results from a meta-analysis including new data. Fachal L; Gómez-Caamaño A; Celeiro-Muñoz C; Peleteiro P; Blanco A; Carballo A; Forteza J; Carracedo A; Vega A Prostate; 2011 Dec; 71(16):1768-79. PubMed ID: 21520156 [TBL] [Abstract][Full Text] [Related]
14. NBS1 is a prostate cancer susceptibility gene. Cybulski C; Górski B; Debniak T; Gliniewicz B; Mierzejewski M; Masojć B; Jakubowska A; Matyjasik J; Złowocka E; Sikorski A; Narod SA; Lubiński J Cancer Res; 2004 Feb; 64(4):1215-9. PubMed ID: 14973119 [TBL] [Abstract][Full Text] [Related]
15. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families. Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464 [TBL] [Abstract][Full Text] [Related]
16. Nationwide study of clinical and molecular features of hereditary non-polyposis colorectal cancer (HNPCC) in Latvia. Irmejs A; Borosenko V; Melbarde-Gorkusa I; Gardovskis A; Bitina M; Kurzawski G; Suchy J; Gorski B; Gardovskis J Anticancer Res; 2007; 27(1B):653-8. PubMed ID: 17348456 [TBL] [Abstract][Full Text] [Related]
17. High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus. Bogdanova NV; Antonenkova NN; Rogov YI; Karstens JH; Hillemanns P; Dörk T Clin Genet; 2010 Oct; 78(4):364-72. PubMed ID: 20569256 [TBL] [Abstract][Full Text] [Related]
18. BRCA1 5382insC founder mutation has not a significative recurrent presence in Northeastern Romanian cancer patients. Negură L; Duşa CP; Balmuş MI; Azoicăi D; Negură AM; Marinca MV; Miron L Rom J Morphol Embryol; 2015; 56(2):379-85. PubMed ID: 26193202 [TBL] [Abstract][Full Text] [Related]
19. The contribution of founder mutations to early-onset breast cancer in French-Canadian women. Ghadirian P; Robidoux A; Zhang P; Royer R; Akbari M; Zhang S; Fafard E; Costa M; Martin G; Potvin C; Patocskai E; Larouche N; Younan R; Nassif E; Giroux S; Narod SA; Rousseau F; Foulkes WD Clin Genet; 2009 Nov; 76(5):421-6. PubMed ID: 19863560 [TBL] [Abstract][Full Text] [Related]
20. Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer? Lener MR; Scott RJ; Kluźniak W; Baszuk P; Cybulski C; Wiechowska-Kozłowska A; Huzarski T; Byrski T; Kładny J; Pietrzak S; Soluch A; Jakubowska A; Lubiński J Int J Cancer; 2016 Aug; 139(3):601-6. PubMed ID: 27038244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]